Find information on thousands of medical conditions and prescription drugs.

Eloxatin

Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin. It is typically administered in combination with fluorouracil and leucovorin in a combination known as FOLFOX for the treatment of colorectal cancer. Compared to cisplatin the two amine groups are replaced by cyclohexyldiamine for improved antitumour activity. The chlorine ligands are replaced by the oxalato bidentate derived from oxalic acid in order to improve water solubility. more...

Home

E-Base

Edecrin

Effexor

Elavil

Elidel

Eligard

Elitek

Elmiron

Elspar

Emtriva

Endep

Enulose

Epi-pen

Epinephrine

Epirubicin

Epitol

Epivir

Epogen

Eryc

Eryped

Esgic

Esmolol

Estrace

Estring

Estrone

Evista

Exelon

Exemestane

Hexal Australia

Oxaliplatin is marketed by Sanofi-Aventis under the trademark Eloxatin®.

Side-effects

Side-effects of oxaliplatin treatment can potentially include:

Neuropathy, specifically including sensitivity to cold and numbness in the hands and feet
Fatigue
Nausea,vomiting, and/or diarrhea
Neutropenia
Hearing loss

In addition, some patients may experience an allergic reaction to platinum-containing drugs.

Read more at Wikipedia.org

• [List your site here Free!]



	New drug approved for colorectal cancer - Updates - Eloxatin Cancers of the colon and rectum (colorectal) are the fourth most commonly diagnosed cancers and rank second among cancer deaths in the United States. From FDA Consumer, 9/1/02

	FDA approves Eloxatin for colorectal cancer - Pamphlet The Food and Drug Administration (FDA) today announced the approval of Eloxatin (oxaliplatin) injection for use in combination with infusional 5-fluorouracil ... From Pamphlet by: U.S. Food and Drug Administration, 8/12/02

	Pharmaceutical: top 50 packages PHARMACEUTICAL From Food & Drug Packaging, 7/1/05

	Gpc Biotech/Debiopharm Sign Mhc Ii Antagonists License Pact GPC Biotech AG (Frankfurt Stock Exchange: GPC; TecDAX 30; NASDAQ: GPCB) and Debiopharm S.A., the independent drug- development company specializing in oncology, endocrinology and niche products, ha From Worldwide Biotech, 2/1/05

	New molecular entity: Vesicare®, Yamanouchi/ GlaxoSmithKline Solifenacin: once-daily therapy approved for overactive bladder Solifenacin was approved for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency. Dosage. The recommended dose of solifenacin is 5 From Geriatrics, 1/1/05

	Sanofi to gain U.S. pharmaceutical share in $65b 'merger of equals' with Aventis Drug store operators soon may be seeing more prescriptions for drugs from Sanofi-Synthelabo come across the counter, as the French pharmaceutical company ... From Drug Store News, 5/17/04 by Michael Johnsen

	FDA approves Avastin In February, the US Food and Drug Administration (FDA) approved Avastin (bevacizumab) for the treatment of advanced colorectal cancer. Avastin is an ... From Townsend Letter for Doctors and Patients, 5/1/04 by Ralph Moss, W.

	Fast-track approval for cancer drug ELOXATIN Approved by the FDA under a 46-day priority review process, Eloxatin (oxaliplatin) injection offers an alternative treatment for patients with ... From Nursing, 11/1/02

Home

Contact

Resources

Exchange Links

ebay